Enabling Future Biologic Drugs and Vaccines
Inaedis RTAD technology enables patient-centric biologic drug administration and shelf stability for pharma, public health and defense innovators.
RTAD Platform for Innovative Biologic Drug Products
Room Temperature Aerosol Dehydration (RTAD)
A scalable and cGMP-compatible biopharmaceutical technology that converts liquid biologics into room-temperature-stable drug formulations and enables various routes of administration.
RTAD unlocks continuous production of biological therapies as powder and suspension drug formulations, enabling unprecedented formulation flexibility for pharma, public health and defense applications.
Core products: Four pathways to innovation
One rtad platform enables multiple drug delivery routes and formulation strategies
Ultra-Concentrated >500 mg/mL mAbs
Subcutaneous injections of monoclonal antibodies
PATIENT BENEFITS
- Reduces administration time by hours
- Enables at-home self-administration
- Saves $150-200K ann. per patient
PHARMA BENEFITS
- Ultra-conc. >500 mg/mL mAbs
- Broader molecule landscape
- Franchise extension vs. biosimilars
Cold Chain-Free Biologics
Room Temperature Stability
PATIENT BENEFITS
- Global access & distribution
- Emerging market deployment
- Simplified storage
DEFENSE/GOV BENEFITS
- Field deployment capability
- Strategic stockpile ready
- Logistics elimination
Inhaled Biologics and Vaccines
Administered with Dry Powder Inhaler
PATIENT BENEFITS
- Eliminates cold chain requirements
- Convenient pulmonary delivery
- Global accessibility
PHARMA BENEFITS
- 5-10x production capacity gain
- Reduced FDA risk & timeline
- Broader molecule landscape
Intranasal Biologics and Vaccines
Administered with Nasal Spray & Powder Device
PATIENT BENEFITS
- Non-invasive administration
- Rapid absorption
- Room-temperature storage
PHARMA BENEFITS
- Non-invasive administration
- Rapid absorption
- Room-temperature storage
Why RTAD Changes the Equation
Capabilities that Conventional Biopharmaceutical Technologies Cannot Unlock
Enabling Biologic Formulations
Biologics that fail traditional drying-based formulation succeed with RTAD, achieving 10–100× less dehydration-induced damage to biologics.
Manufacturing De-Risk
Retrofit existing cGMP spray dryers instead of investing over $50M in greenfield facilities. RTAD offers a 12–18 month proven scale-up with digital twin validation.
Operational Capability
Room-temperature stability enables field deployment, creation of strategic stockpiles, and surge manufacturing for defense readiness.
Franchise Protection
Formulation IP blocks biosimilars for 5–7 years. Extend aging franchises against $120B patent cliffs through 2030.
Capacity Gains
Achieve 5–10× manufacturing capacity from existing infrastructure. Digital twin CFD predictive modeling helps to de-risk the scale-up process.
Speed to Clinic
RTAD provides a proven 100× feedstock scale-up within 12–18 months, compared to over 24 months for alternative methods. The consistent process is aligned with FDA-ready CMC standards.
Validation & Commercial Traction
Technical achievements, pharma validation and Market proof
✅
SuspensiFlow Proven
>500 mg/mL mAb, 27G needle, <10N injection force, no aggregates
📈
100× Scale-Up
Consistent droplet size across 1→100 mL/min feedstock increase. Digital twin CFD validated.
🤝
Partnerships
Merck Digital Sciences Studio completed. Feasibility studies in negotiation for SC program.
🔬
Industry Validation
10× inhaled capacity validated by Top 10 Pharma company. Joint study on scale-up to pilot production is underway.
🎓
Technology from Princeton University
Exclusive license on core tech. 10+ peer-reviewed publications. Patents through 2040s.
💰
Awards and Non-Dilutive Funding
NSF SBIR Phase I and II, NIH STTR Phase I, DoW SBIR Phase I, NJ CSIT backing. Market validation via government agencies.
Supported by
Latest News:
Inaedis Awarded Competitive SBIR Phase I Contract from the U.S. Department of Defense
DoD SBIR Program Provides Funding to Advance Thermostable Biologic and Vaccine Formulations PRINCETON, NEW JERSEY – September 8, 2025 – Inaedis Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) contract from the U.S. Department of Defense (DoD) in the amount of $209,565 to advance development of its Rapid Room-Temperature Aerosol Dehydration…
Inaedis Wins Prestigious NSF SBIR Phase II Award to Revolutionize Biologic Drug Stability
PRINCETON, NEW JERSEY (June 17, 2025) – Inaedis, Inc. is thrilled to announce it has been awarded a highly competitive $1.25 million Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF), under Award Number 2451720. This major funding milestone will propel Inaedis’ development of its breakthrough Rapid Room-Temperature Aerosol Dehydration…
Inaedis Selected for Merck Digital Sciences Studio Cohort
PRESS RELEASE Princeton, NJ, Nov 19, 2024 – Inaedis is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer…